search
Back to results

Hyperglycemia and Exercise. (GlucotoxEx)

Primary Purpose

Aerobic Exercise, Hyperglycemia, Glucose Metabolism Disorders (Including Diabetes Mellitus)

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Steady-state hyperglycemia
Fluctuating hyperglycemia
Exercise
Sponsored by
University of Birmingham
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Aerobic Exercise

Eligibility Criteria

18 Years - 50 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Male
  • Aged between 18 and 50 years.
  • Body Mass Index of between 19 and 30 kg/m2.

Exclusion Criteria:

  • Smoking.
  • Regularly use of anti-inflammatory medication.
  • More than 2 kg weight change in the last 6 months, and/or have undergone weight loss surgery.
  • Previous or current cancer or chronic haematological, pulmonary, cardiac, hepatic, renal, metabolic, or gastrointestinal diseases.
  • Currently engaged in moderate or vigorous exercise on more than 5 days per week.
  • Contraindication to exercise.

Sites / Locations

  • University of Birmingham

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Other

Experimental

Experimental

No Intervention

Arm Label

Normal glycemia + exercise

Steady-state hyperglycemia + exercise

Fluctuating hyperglycemia + exercise

Normal glycemia, no exercise

Arm Description

Participants will be studied in the fasting state under normal blood glucose conditions whereby no glucose will be administered, but an exercise bout will be completed.

Participants will be studied during experimental steady-state hyperglycemia-induced via a variable-rate intravenous glucose infusion, and an exercise bout will be completed.

Participants will be studied during experimental fluctuating hyperglycemia-induced via repeated intravenous glucose injections, and an exercise bout will be completed.

Participants will be studied in the fasting state under normal blood glucose conditions whereby no glucose will be administered and no exercise will be completed.

Outcomes

Primary Outcome Measures

Exercise-induced change in blood glucose control.
In all trials, continuous glucose monitoring (CGM) will be used to assess the change in glucose control compared to baseline for 24 hours after-exercise, under diet-controlled but otherwise free-living conditions.

Secondary Outcome Measures

Hyperglycemia-induced change in inflammation.
In all trials, plasma cytokine levels (IL-6, TNF-alpha, IL-1ra) will be measured at baseline (T=0 hours) and immediately after each glycaemic intervention (T=3.5 hours). The interventions will take place between baseline (T=0 hours) and T=3.5 hours.
Hyperglycemia-induced change in cognitive function.
In all trials, cognitive function tests (CANTAB) to measure executive functioning and verbal memory will be administered at baseline (T=0 hours) and immediately after each glycaemic intervention (T=3.5 hours). The interventions will take place between baseline (T=0 hours) and T=3.5 hours.

Full Information

First Posted
February 28, 2017
Last Updated
December 10, 2018
Sponsor
University of Birmingham
search

1. Study Identification

Unique Protocol Identification Number
NCT03284216
Brief Title
Hyperglycemia and Exercise.
Acronym
GlucotoxEx
Official Title
The Effects of Hyperglycemia on the Response to Acute Exercise.
Study Type
Interventional

2. Study Status

Record Verification Date
December 2018
Overall Recruitment Status
Completed
Study Start Date
August 1, 2017 (Actual)
Primary Completion Date
November 30, 2018 (Actual)
Study Completion Date
December 8, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Birmingham

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will determine whether exposure to short-term high blood glucose levels impairs exercise-induced adaptations in glucose tolerance, and whether the pattern of high blood glucose levels plays a role.
Detailed Description
Healthy male volunteers will undergo a screening visit and four experimental trials. Screening Visit: Having read the participant info sheet, a study investigator will discuss the project with the potential participant who will have the chance to ask any questions. Informed consent will be sought and a General Health Questionnaire will be completed. Body weight, height, and skinfold measurements will be taken. Participants will also complete an exercise test to measure V̇O2max test along with heart rate and blood pressure measurements. Individuals eligible for inclusion in the study will then return to the lab for four experimental trials, each separated by ~1 week. Trials will be completed using a randomised, counter-balanced, cross-over design. Between experimental trials, participants will be instructed to maintain their normal diet and activity habits. During the 48 hours prior to each experimental trial participants will be instructed to refrain from vigorous exercise and alcohol. For 3 days prior to each experimental trial, participants will record their dietary intake, and wear an accelerometer and a continuous glucose monitor to measure physical activity levels and glucose control. Experimental Trials: Participants will arrive at the laboratory in the morning (~8 am) following an overnight (~10 hour) fast from food and drink (except water) since 10pm the previous evening. Upon entering the laboratory, body composition (height, weight, waist circumference) will be assessed and a cannula will be placed into a vein in each arm (one for infusion of glucose, one for blood sampling). Resting cardiovascular measures (heart rate, blood pressure, oxygen saturation) will be collected followed by an assessment of cognitive function followed immediately by one of the four 3.5 hour interventions: Trial A (normoglycaemia prior to exercise): This will involve no glycaemic intervention and the participant will remain in a rested, normoglycaemic state throughout all subsequent procedures. Trial B (steady hyperglycaemia prior to exercise): This will involve a continuous constant-rate glucose infusion to establish a steady hyperglycaemic profile. Specifically, 1.2g/kg glucose will be infused at a constant infusion rate across 3.5 hrs (equivalent to 5.71 mg/kg/min). Trial C (fluctuating hyperglycaemia prior to exercise): This will involve repeated glucose injections so as to cause multiple fluctuations in glycaemia. Specifically, 1.2 g/kg glucose will be infused via 8 equal boluses every 30 minutes across 3.5 hrs (the equivalent of 0.15 g/kg per bolus infused over 3.5 minutes at a rate of 42.86 mg/kg/min) interspersed with periods of no infusion. Trial D (normoglycaemia, no exercise): This will be identical to trial A, except there will be no exercise bout. After 3.5 hours, the above-described glycaemic intervention will stop, and be followed immediately by the collection of post-intervention blood samples, assessment of cardiovascular response and assessment of cognitive function. Participants will then complete an exercise bout consisting of 45 minutes of moderate intensity (70% HRmax) continuous cycling, during which energy expenditure will be measured by indirect calorimetry. Post-exercise blood samples will be collected, and catheters will be removed. Participants will be fed a meal. Before leaving the lab, they will also be provided with an evening meal to be consumed at home at 7 pm, and a breakfast and lunch meal for the following day (to be consumed at 7 am and 12 pm, respectively). Participants will then return to the laboratory for 5 minutes the afternoon after the trial day (~3 pm) to remove the accelerometer and continuous glucose monitor, marking the end of the trial.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Aerobic Exercise, Hyperglycemia, Glucose Metabolism Disorders (Including Diabetes Mellitus)

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Normal glycemia + exercise
Arm Type
Other
Arm Description
Participants will be studied in the fasting state under normal blood glucose conditions whereby no glucose will be administered, but an exercise bout will be completed.
Arm Title
Steady-state hyperglycemia + exercise
Arm Type
Experimental
Arm Description
Participants will be studied during experimental steady-state hyperglycemia-induced via a variable-rate intravenous glucose infusion, and an exercise bout will be completed.
Arm Title
Fluctuating hyperglycemia + exercise
Arm Type
Experimental
Arm Description
Participants will be studied during experimental fluctuating hyperglycemia-induced via repeated intravenous glucose injections, and an exercise bout will be completed.
Arm Title
Normal glycemia, no exercise
Arm Type
No Intervention
Arm Description
Participants will be studied in the fasting state under normal blood glucose conditions whereby no glucose will be administered and no exercise will be completed.
Intervention Type
Procedure
Intervention Name(s)
Steady-state hyperglycemia
Other Intervention Name(s)
Drug (metabolite infusion)
Intervention Description
Experimental "diabetic like" steady-state hyperglycemia will be induced via a continuous-rate intravenous glucose infusion.
Intervention Type
Procedure
Intervention Name(s)
Fluctuating hyperglycemia
Other Intervention Name(s)
Drug (metabolite injection)
Intervention Description
Experimental "diabetic like" fluctuating hyperglycemia will be induced via repeated intravenous glucose injections.
Intervention Type
Behavioral
Intervention Name(s)
Exercise
Intervention Description
Moderate-intensity exercise bout (45-minutes of cycling at 70% of their heart rate max) at T=4.5 hours
Primary Outcome Measure Information:
Title
Exercise-induced change in blood glucose control.
Description
In all trials, continuous glucose monitoring (CGM) will be used to assess the change in glucose control compared to baseline for 24 hours after-exercise, under diet-controlled but otherwise free-living conditions.
Time Frame
In all trials, glucose control will be determined between the time-point immediately after exercise and 24 hours after exercise.
Secondary Outcome Measure Information:
Title
Hyperglycemia-induced change in inflammation.
Description
In all trials, plasma cytokine levels (IL-6, TNF-alpha, IL-1ra) will be measured at baseline (T=0 hours) and immediately after each glycaemic intervention (T=3.5 hours). The interventions will take place between baseline (T=0 hours) and T=3.5 hours.
Time Frame
In all trials, inflammation will be determined at baseline (T=0 hours) and at T=3.5 hours. The glycemic interventions take place between baseline (T=0 hours) and T=3.5 hours.
Title
Hyperglycemia-induced change in cognitive function.
Description
In all trials, cognitive function tests (CANTAB) to measure executive functioning and verbal memory will be administered at baseline (T=0 hours) and immediately after each glycaemic intervention (T=3.5 hours). The interventions will take place between baseline (T=0 hours) and T=3.5 hours.
Time Frame
In all trials, cognitive function will be determined at baseline (T=0 hours) and at T=3.5 hours. The glycemic interventions take place between baseline (T=0 hours) and T=3.5 hours.

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male Aged between 18 and 50 years. Body Mass Index of between 19 and 30 kg/m2. Exclusion Criteria: Smoking. Regularly use of anti-inflammatory medication. More than 2 kg weight change in the last 6 months, and/or have undergone weight loss surgery. Previous or current cancer or chronic haematological, pulmonary, cardiac, hepatic, renal, metabolic, or gastrointestinal diseases. Currently engaged in moderate or vigorous exercise on more than 5 days per week. Contraindication to exercise.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas P Solomon, PhD
Organizational Affiliation
University of Birmingham
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Birmingham
City
Birmingham
State/Province
West Midlands
ZIP/Postal Code
B15 2TT
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
33178135
Citation
Carter S, Solomon TPJ. Exercise-Induced Improvements in Postprandial Glucose Response Are Blunted by Pre-Exercise Hyperglycemia: A Randomized Crossover Trial in Healthy Individuals. Front Endocrinol (Lausanne). 2020 Oct 15;11:566548. doi: 10.3389/fendo.2020.566548. eCollection 2020.
Results Reference
derived

Learn more about this trial

Hyperglycemia and Exercise.

We'll reach out to this number within 24 hrs